These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 33140259)

  • 21. FDAMA Section 114: Why the Renewed Interest?
    Perfetto EM; Burke L; Oehrlein EM; Gaballah M
    J Manag Care Spec Pharm; 2015 May; 21(5):368-74. PubMed ID: 25942998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating Literature for Oncology Data Gaps to Improve the Quality of Standard Response Letters: A Retrospective Review.
    Monestime S
    Ther Innov Regul Sci; 2020 Mar; 54(2):385-389. PubMed ID: 32072589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary.
    Chren MM; Landefeld CS
    JAMA; 1994 Mar; 271(9):684-9. PubMed ID: 8309031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Critical Care Network in the State of Qatar.
    Hijjeh M; Al Shaikh L; Alinier G; Selwood D; Malmstrom F; Hassan IF
    Qatar Med J; 2019; 2019(2):2. PubMed ID: 31763205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proposed Best Practice Guidelines for Scientific Response Documents: A Consensus Statement from phactMI.
    Hermes-DeSantis ER; Johnson RM; Redlich A; Patel B; Flanigan-Minnick A; Wnorowski S; Cortes MM; Han CW; Vine E; Sarwar H; Haydar R; Jamil A; Huang T; Sandhu SK; Reilly P
    Ther Innov Regul Sci; 2020 Nov; 54(6):1303-1311. PubMed ID: 33258092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. UK accident and emergency departments and emergency contraception: what do they think and do?
    Gbolade BA; Elstein M; Yates D
    J Accid Emerg Med; 1999 Jan; 16(1):35-8. PubMed ID: 9918285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survey of Customers Requesting Medical Information: Preferences and Information Needs of Patients and Health Care Professionals to Support Treatment Decisions.
    Fung SM; Sud C; Suchodolski M
    Ther Innov Regul Sci; 2020 Jan; 54(1):75-84. PubMed ID: 32008254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
    Dunlop WCN; Staufer A; Levy P; Edwards GJ
    Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health economics in the Canadian pharmaceutical industry.
    Assiff L; Pollock MR; Manzi P; Faienza B; Menon D
    Pharmacoeconomics; 1999 Dec; 16(6):669-78. PubMed ID: 10724794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.
    Garrison LP; Carlson JJ; Bajaj PS; Towse A; Neumann PJ; Sullivan SD; Westrich K; Dubois RW
    Am J Manag Care; 2015 Sep; 21(9):632-40. PubMed ID: 26618366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians.
    Miller RM; Happe LE; Meyer KL; Spear RJ
    J Manag Care Pharm; 2012; 18(1):54-62. PubMed ID: 22235955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [ENT expert assessment for federal health insurance in North Rhine. A contribution to the internal discussion of quantitative and qualitative optimization of the expert witness process].
    Lauven G; Buszello HP; Müller-Held W
    Gesundheitswesen; 1999 Apr; 61(4):179-84. PubMed ID: 10408144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Information provided by generic and brand-name pharmaceutical manufacturers in response to a request.
    Fernandez-Llimos F; Vazquez Gomez I
    Pharm World Sci; 2007 Dec; 29(6):683-7. PubMed ID: 17464571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality management benchmarking: FDA compliance in pharmaceutical industry.
    Jochem R; Landgraf K
    Int J Health Care Qual Assur; 2010; 23(8):690-8. PubMed ID: 21125964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. International benchmarking and best practice management: in search of health care and hospital excellence.
    von Eiff W
    Adv Health Care Manag; 2015; 17():223-52. PubMed ID: 25985514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medical Information Practices Across the Pharma Industry: What Can We Learn from Benchmarking Surveys?
    Shah I; Janajreh I; Fung SM
    Ther Innov Regul Sci; 2020 Nov; 54(6):1259-1262. PubMed ID: 33180311
    [No Abstract]   [Full Text] [Related]  

  • 37. Descriptive review and analysis of immunoglobulin utilization management from 2,548 prior authorization requests.
    Tonkovic B; Rutishauser LK
    J Manag Care Spec Pharm; 2014 Apr; 20(4):357-67. PubMed ID: 24684640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medical Information Services: How Are We Trending?
    Bordoloi P; Gažo A; Savulich D; Verzosa C
    Ther Innov Regul Sci; 2014 Nov; 48(6):NP15-NP21. PubMed ID: 30227461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts.
    Kannarkat JT; Good CB; Kelly E; Parekh N
    J Manag Care Spec Pharm; 2020 Jan; 26(1):63-66. PubMed ID: 31880231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical Information Delivering Improved Customer Experience: A Guide.
    Guillot P; Shea J; Shoemaker S; Rocco M; DeLuca M; Rai R; Hermes-DeSantis ER
    Pharmaceut Med; 2023 Mar; 37(2):111-119. PubMed ID: 37017877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.